Food and Drug Administration Approvals.

Aciphex (rabeprazole) is now indicated for the eradication of Helicobacter pylori.
Previously, Aciphex was indicated for the communication of gastroesophageal ebb disease (GERD).

Helicobacter pylori eradication to reduce the risk of duodenal ulcer recurrence:

Aciphex, in social unit with amoxicillin and clarithromycin as a 3-drug regimen, is indicated for the communicating of patients with H pylori corruption and duodenal ulcer disease (active or story within the past 5 years) to eradicate H pylori.
Eradication of H pylori has been shown to reduce the risk of duodenal ulcer recurrence.
In patients who fail therapy, susceptibility investigating should be done.
If status to clarithromycin is demonstrated or susceptibility experimentation is not possibility, alternative antimicrobial therapy should be instituted.

Dosing:H pylori eradication requires a 3-drug regimen to be taken twice daily with the period of time and eve meals.

Aciphex 20 mg twice daily for 7 days

Amoxicillin 1000 mg twice daily for 7 days

Clarithromycin 500 mg twice daily for 7 days

Clinical Summary: A US multicenter, double-blind, parallel-group comparability of rabeprazole, amoxicillin, and clarithromycin for 3, 7, or 10 days vs omeprazole, amoxicillin, and clarithromycin for 10 days was conducted.
Therapy consisted of rabeprazole 20 mg twice daily, amoxicillin 1000 mg twice daily, and clarithromycin 500 mg twice daily (RAC) or omeprazole 20 mg twice daily, amoxicillin 1000 mg twice daily, and clarithromycin 500 mg twice daily (OAC).
This is a part of article Food and Drug Administration Approvals. Taken from "Generic Aciphex (Rabeprazole) Review" Information Blog